Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven non-small cell lung cancer with at least 1 lesion accessible for endobronchial or percutaneous injection
• Measurable or evaluable disease
• Must have a requirement for palliative radiotherapy to the thorax
• Clinically stable enough to undergo 3 adenovirus injections
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0 or 1
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• PT and PTT normal
• Renal:
• Not specified
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Other:
• No active systemic viral, bacterial, or fungal infection requiring treatment
• No concurrent illness requiring hospitalization or IV medications or psychologic, familial, sociologic, geographic, or other concurrent condition that would preclude adequate follow up and compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior adenoviral gene therapy
• Any number of any type of other prior biologic therapy allowed
• Chemotherapy:
• Any number of any type of prior chemotherapy allowed
• At least 2 weeks since prior systemic cancer therapy and no worse than grade 2 toxicity in any organ
• Endocrine therapy:
• Any number of any type of prior endocrine therapy allowed
• Radiotherapy:
• See Disease Characteristics
• No prior radiotherapy greater than 50 Gy if prior and concurrent radiation fields include the spinal cord
• No prior radiotherapy in fraction sizes greater than 2 Gy with the spinal cord in the concurrent radiation field
• Surgery:
• At least 4 weeks since surgical resection of lung tissue
• At least 2 weeks since any other prior surgery requiring general anesthesia and recovered